Off-label drug prescriptions in French general practice: a cross-sectional study.


Journal

BMJ open
ISSN: 2044-6055
Titre abrégé: BMJ Open
Pays: England
ID NLM: 101552874

Informations de publication

Date de publication:
09 04 2019
Historique:
entrez: 11 4 2019
pubmed: 11 4 2019
medline: 21 4 2020
Statut: epublish

Résumé

Off-label drug prescribing is a public health and economic issue. The aim of this study was to describe off-label prescription in general practice in France, in terms of frequency and nature, and to identify its main determining factors. Multicentre cross-sectional study SETTING: Twenty-three training general practice offices PARTICIPANTS: All the voluntary patients coming for a medical consultation or visited at home over a cumulative period of 5 days per office between November 2015 and January 2016. Eleven interns, acting as observers, collected data. Two reviewers analysed the drugs prescribed by the trainers, in order to identify those prescribed off-label in terms of their indication or the age of the patient. We used a univariate, then a multivariate model, based on hierarchical mixed-effects logistic regression. Among the 4932 drug prescriptions registered, 911 (18.5%[95% CI17.4% to 19.6%]) were off-label, of which 865 (17.6%) due to the indication of the drug and 58 (1.2%) due to the age of the patient. The prescription never mentioned the off-label use, neither was the patient informed of it, as required by the French law. With the multivariate analysis, variables contributing to off-label prescription were the number of drugs (OR=1.05 for each additional drug), the initiation of new drug therapy (OR=1.26) and the non-specific goal of the prescription (OR=1.43); the age of the patient ≤14 years (OR=1.42); the rural location of the physician's practice (OR=1.38) and the low frequency of the visits of national health insurance representatives (OR=0.93). Almost one out of five drugs prescribed in French general practice was off-label. It seems necessary to better train physicians in clinical pharmacology, to provide them with more effective drug prescription software, to reinforce postmarketing surveillance and to clearly define off-label use by consensus.

Identifiants

pubmed: 30967407
pii: bmjopen-2018-026076
doi: 10.1136/bmjopen-2018-026076
pmc: PMC6500201
doi:

Types de publication

Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

e026076

Informations de copyright

© Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: None declared.

Références

BMC Med Educ. 2016 Apr 27;16:126
pubmed: 27117188
Eur J Clin Pharmacol. 2003 Aug;59(4):263-70
pubmed: 12759794
Pediatrics. 2014 Mar;133(3):563-7
pubmed: 24567009
Front Immunol. 2015 Dec 11;6:625
pubmed: 26697019
Br J Clin Pharmacol. 2012 Jan;73(1):12-5
pubmed: 21470290
Pediatrics. 2014 Nov;134(5):e1474-502
pubmed: 25349312
PLoS Med. 2010 Oct 19;7(10):e1000352
pubmed: 20976098
Eur J Clin Pharmacol. 2012 Jan;68(1):21-8
pubmed: 21779968
N Engl J Med. 2003 Apr 17;348(16):1556-64
pubmed: 12700376
N Engl J Med. 2012 Oct 4;367(14):1279-81
pubmed: 23034018
Pharmacopsychiatry. 2007 May;40(3):116-20
pubmed: 17541887
J Manag Care Pharm. 2004 May-Jun;10(3):234-8
pubmed: 15228373
Int J Clin Pharm. 2018 Jun;40(3):509-512
pubmed: 29721740
JAMA Intern Med. 2016 Jan;176(1):55-63
pubmed: 26523731
Am Fam Physician. 2006 Sep 15;74(6):956-66
pubmed: 17002029
BMC Health Serv Res. 2020 Jan 2;20(1):6
pubmed: 31898496
Paediatr Respir Rev. 2007 Jun;8(2):177-83
pubmed: 17574163
Eur J Pediatr. 2005 Sep;164(9):552-8
pubmed: 15912383
Ann Oncol. 2007 Dec;18(12):1923-5
pubmed: 18083693
N Engl J Med. 2008 Apr 3;358(14):1427-9
pubmed: 18385495
Dtsch Med Wochenschr. 2013 Oct;138(44):2239-45
pubmed: 24150699
Pediatrics. 2015 Jan;135(1):49-58
pubmed: 25511119
Pharm World Sci. 2007 Apr;29(2):97-100
pubmed: 17160629
PLoS One. 2012;7(3):e24061
pubmed: 22403604
J Clin Gastroenterol. 2012 Feb;46(2):93-114
pubmed: 22227731
Arch Intern Med. 2006 May 8;166(9):1021-6
pubmed: 16682577
Clin Pharmacol Ther. 2012 May;91(5):787-95
pubmed: 22472983
Ann Pharm Fr. 2008 Nov-Dec;66(5-6):268-77
pubmed: 19061726

Auteurs

François Drogou (F)

Univ. Lyon, Université Claude Bernard Lyon 1, Université Saint-Étienne, Collège universitaire de médecine générale, F-69008 Lyon, F-42023 Saint-Étienne, Département de médecine générale, Lyon, France.

Allison Netboute (A)

Univ. Lyon, Université Claude Bernard Lyon 1, Université Saint-Étienne, Collège universitaire de médecine générale, F-69008 Lyon, F-42023 Saint-Étienne, Département de médecine générale, Lyon, France.

Joris Giai (J)

Service de Biostatistique, Centre Hospitalier Universitaire de Lyon, Lyon, France.

Xavier Dode (X)

Département de pharmacie, Centre Hospitalier Universitaire de Lyon, Lyon, France.

David Darmon (D)

Département d'enseignement et de recherche en Médecine Générale, Universite de Nice Faculte de Medecine, Nice, France.

Behrouz Kassai (B)

EPICIME-Centre d'Investigation Clinique, INSERM CIC201/UMR5558, Hôpital Louis Pradel, Lyon, France.
UMR 5558, CNRS Lyon, University of Lyon 1, Lyon, France.

Laurent Letrilliart (L)

Univ. Lyon, Université Claude Bernard Lyon 1, Université Saint-Étienne, Collège universitaire de médecine générale, F-69008 Lyon, F-42023 Saint-Étienne, Département de médecine générale, Lyon, France.
Univ. Lyon, Université Claude Bernard Lyon 1, Université Saint-Étienne, HESPER EA 7425, F-69008 Lyon, F-42023 Saint-Étienne, France, E.A. 4129 « Santé, Individu, Société », Lyon, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH